



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification<sup>6</sup>:</b> <b>C12N 5/10, A61K 35/48, C07K 16/18,</b> <b>G01N 33/50</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 97/28255</b> <b>(43) International Publication Date:</b> 7 August 1997 (07.08.97)
<b>(21) International Application Number:</b> PCT/US97/01430 <b>(22) International Filing Date:</b> 30 January 1997 (30.01.97) <b>(30) Priority Data:</b> 60/011,042      2 February 1996 (02.02.96)      US <b>(60) Parent Application or Grant</b> <b>(63) Related by Continuation</b> US      60/011,042 (CIP) Filed on      2 February 1996 (02.02.96) <b>(71) Applicant (for all designated States except US):</b> THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES [US/US]; Office of Technology Transfer, National Institutes of Health, Suite 325, 6011 Executive Boulevard, Rockville, MD 20852 (US). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> TOPALIAN, Suzanne, L. [US/US]; 19400 James Creek Court, Brookeville, MD 20833 (US). LINEHAN, W., Marston [US/US]; 7009 Tilden Lane, North Bethesda, MD 20852 (US). BRIGHT, Robert, K. [US/US]; 14163 Furlong Way, Germantown, MD 20874		<b>(US).</b> VOCKE, Cathy, D. [US/US]; 20533 Golf Course Drive, Germantown, MD 20874 (US). <b>(74) Agents:</b> FEILER, William, S. et al.; Morgan & Finnegan, L.L.P., 345 Park Avenue, New York, NY 10154 (US). <b>(81) Designated States:</b> CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> IMMORTAL HUMAN PROSTATE EPITHELIAL CELL LINES AND CLONES AND THEIR APPLICATIONS IN THE RESEARCH AND THERAPY OF PROSTATE CANCER		
<b>(57) Abstract</b> <p>The present invention relates to immortalized, malignant, human, adult prostate epithelial cell lines or cell lines derived therefrom useful in the diagnosis and treatment of prostate cancer. More particularly, the present invention relates to cloned, immortalized, malignant, human, adult prostate epithelial cell lines and uses of these cell lines for the diagnosis and treatment of cancer. Furthermore, the present invention provides for the characterization of said cell lines through the analysis of specific chromosomal deletions.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

- 1 -

## IMMORTAL HUMAN PROSTATE EPITHELIAL CELL LINES AND CLONES AND THEIR APPLICATIONS IN THE RESEARCH AND THERAPY OF PROSTATE CANCER

### FIELD OF THE INVENTION

The present invention relates to immortalized, malignant, human adult prostate epithelial cell lines. The invention also relates to single cell clones of these lines. The invention further relates to immortalized, malignant, human, adult prostate epithelial cell lines and clones characterized by analysis of allelic loss of heterozygosity. More particularly, the invention relates to pairs of autologous normal and malignant prostate epithelial cell lines and clones and their applications in research. The invention also relates to the uses of the cells in the diagnosis and treatment of prostate cancer.

### BACKGROUND OF THE INVENTION

Difficulty in establishing long term human prostatic cancer cell lines in vitro has impeded progress toward the understanding of prostate tumorigenesis and the development of new therapies for prostate cancer. To date only four prostate cancer cell lines, initiated from metastatic lesions, have provided the basis for the majority of *in vitro* experiments concerning the biological and molecular events regulating prostate tumorigenesis. Accordingly, there is an enormous academic, diagnostic, and therapeutic need for established long-term prostate cancer cell cultures.

In recent years, prostate cancer has emerged as the most commonly diagnosed cancer in men in the United States. In this year alone, new cases of prostate cancer are estimated to approach 300,000 with over 40,000 deaths, resulting in a cancer mortality rate second only to lung cancer (1). Although prostate cancer mortality commonly results from metastatic disease, nearly 60% of newly diagnosed patients present with localized primary tumors. Surgery and radiation therapy are often effective in treating localized disease, but disseminated metastatic disease is largely untreatable. Despite considerable scientific effort there is still relatively little known about the biological events causing the initiation

-2-

and progression of prostate cancer. The development of new strategies for the treatment of adenocarcinoma of the prostate necessitates an increased understanding of the cellular and molecular events involved in the generation of primary prostate cancer and its metastatic progression.

5 Four human prostate cancer cell lines (LNCaP, DU145, PC-3, TSU-Pr1), initiated from metastatic lesions, have provided the basis for the majority of in vitro experiments concerning prostate cancer. Extensive progress has been made towards the *in vitro* cultivation of short-term lines from primary (nonmetastatic) prostate cancers. The advances have included culture media development and  
10 improvements in fresh tissue preparation and prostate epithelial cell culture techniques (3,4). However, the establishment and maintenance of long-term human prostate epithelial cell lines from primary tumors has been unsuccessful in the absence of *in vitro* immortalization. To this end, there exist only a small number of reports describing long-term immortalized cell lines, and these have been limited  
15 to normal prostatic epithelial cultures (5,6,7,8). Thus, the goal of the current study was to develop reliable methods for generating continuously proliferating prostate cancer cell lines derived from primary tumors.

Beyond the difficulties inherent in establishing immortal prostate epithelial cell lines are the problems associated with distinguishing cultivated  
20 prostate cancer from normal epithelial cells. Past cytogenetic evaluation of multiple short-term prostate epithelial cell cultures has revealed that the majority of lines generated from localized prostate cancers exhibit a normal male karyotype (9,10,11). This, combined with the unremarkable microscopic morphology of short-term cultures and a pervasive lack of success with xenotransplantation, has  
25 rendered accurate identification and characterization of human primary prostate cancer cell lines extremely difficult.

The initiation of prostate cancer is believed to occur as a result of multiple genetic changes within the cell, including the inactivation of potential tumor suppressor genes as manifested by allelic chromosomal deletions (reviewed  
30 in 12). Early studies examining chromosomal deletions in fresh (noncultured) primary prostate cancer specimens exhibited allelic loss of heterozygosity (LOH) on chromosomes 10q and 16q (13,14,15). Subsequent studies demonstrated a

-3-

remarkably high percentage of allelic loss on the short arm of chromosome 8, thus moving chromosome 8p to the forefront of the list of potential sites for prostate cancer- associated tumor suppressor genes (16,17,18). Moreover, recent examination of 99 microdissected tumors (19) and 54 micro-dissected PIN lesions (20) for LOH on the short arm of chromosome 8p demonstrated strong evidence for the inactivation of a tumor suppressor gene(s) on chromosome 8p12-21 when compared to matched normal controls. Accordingly, examination of LOH within this minimal deletion region on chromosome 8p12-21 represents a potentially powerful alternative method for the identification and characterization of human prostate epithelial cell lines derived from primary tumors.

The present invention is the successful generation and unique genetic characterization of multiple immortalized human tumor cell lines derived from primary adenocarcinomas of the prostate.

#### **SUMMARY OF THE INVENTION**

The present invention provides for the isolation, immortalization, and characterization of long-term human epithelial cell lines derived from cancerous and normal prostate tissue and the potential applications of these cell lines in the research and therapy of prostate cancer. Specifically, the objects of the present invention are achieved using prostate epithelial cell lines with unlimited proliferation potential derived from both malignant and benign autologous specimens.

The cell lines of the present invention are useful as models in epithelial cell oncogenesis studies. For example, the immortalized epithelial prostate cell lines of the present invention are particularly useful for understanding the tumorigenesis of prostate cancer. The present invention provides for immortalized benign adult prostate cell lines for use in combination with immortalized, autologous malignant adult prostate cell lines as reagents for defining the genetic events leading from the benign to the malignant cellular phenotype, and for investigating the role of heredity in prostate cancer.

The present invention is an isolated, immortalized, malignant, human adult prostatic epithelial cell line. Another aspect of the invention is a cloned immortalized, malignant adult prostatic epithelial cell line characterized as having

-4-

at least one allelic loss of heterozygosity (LOH). A further aspect of the invention is a cloned, immortalized, malignant, human adult prostatic epithelial cell line characterized as having loss of one or more alleles on chromosome 1, 8p, 10 and/or 16.

5           The cell lines of the present invention can be utilized in a method of producing a preselected protein and a method of producing proteins of epithelial cell origin. For example, the cell lines of the present invention are useful for the isolation of malignant prostate-associated proteins which could serve as markers for diagnosis or targets for immunotherapy. In one embodiment of the invention, a  
10       method for the production of proteins is provided comprising the steps of culturing the epithelial cell lines of the present invention and collecting one or more proteins produced by the novel cells. Identification of the genes encoding such proteins, using standard scientific practice, would enable construction of recombinant vectors for efficient large-scale production of the protein or portion thereof.

15           The cell lines of the present invention are also useful for testing the effects of therapeutic agents against prostate cancer in vitro, for example, chemotherapeutic drugs, biologic response modifiers, or genetic reagents such as anti-sense oligonucleotides.

20           The cell lines of the present invention are also useful as a whole cell vaccine for treating or preventing the recurrence of prostate cancer. The whole cell vaccine may be administered in the native form, in combination with adjuvants, or as modified by transgenes encoding, for example, various cytokines, chemokines, adhesion molecules, or MHC molecules.

25           The cell lines of the present invention are also therapeutically useful as stimulants for raising prostate cancer-reactive antibodies or immune cells from peripheral blood or lymph node cells for administration to prostate cancer patients.

30           The present invention also provides for immortal prostate cell lines for use in molecular cloning of malignant prostate-associated antigens recognized by the immune system. These antigens are then developed into recombinant vaccines directed to the prevention or cure of prostate cancer.

          The present invention further provides for pharmaceutical compositions comprising one or more of the immortal cell lines of the present

-5-

invention, and for pharmacological, therapeutic and diagnostic uses for the immortal cell lines and pharmacological compositions comprising the same.

These and other objects of the present invention will become apparent in light of the accompanying disclosure and annexed figures.

5

### **BRIEF DESCRIPTION OF THE DRAWINGS**

Figure 1A and 1B. Morphologic and growth characteristics of an immortalized prostate epithelial cell line. (1A) Immortalization with the retrovirus LXSN16E6E7 was necessary to achieve continued proliferation of culture 1510-CP, initiated from a prostate cancer specimen. Cells were transduced (1510-CPTX) or not (1510-CPNV) at culture passage 3, and proliferation in 24-well plates was monitored at passages 10 and 5, respectively. (1B) Photomicrograph of 1510-CPTX after 10 culture passages (200 x, phase contrast). This culture appearance is typical of other prostate epithelial cell lines generated from benign or malignant specimens.

15

Figure 2. Expression of PSA by benign and malignant prostate epithelial cells *in situ*. A paraffin-embedded tissue section from the radical prostatectomy specimen from patient 1510 contains areas of invasive prostate cancer (single arrow) as well as normal prostatic epithelium (double arrows). Dark pigmentation indicates binding of an anti-PSA monoclonal antibody. While PSA expression by normal prostatic epithelial cells is intense and homogeneous, expression by cancer cells is weak and heterogeneous. Intervening stromal cells do not express PSA. (200 x).

20

Figure 3. Genetic map of chromosome 8p identifying the relative location of the microsatellite markers used for loss of heterozygosity analysis.

25

Figure 4. PCR analysis of microsatellite D8S136 on fresh and cultured cells from patient 1542. Lane 1, 1542-NPTX, passage 26. Lane 2, fresh microdissected tumor #11. Lane 3, uncloned 1542-CP,TX, passage 21. Lanes 4-6, tumor clones 1542-CP,TX.8.1, 1542-CP,TX.8.3 and 1542-CP,TX.8.4, derived from the 8th passage of 1542-CP,TX.

30

Figure 5A - 5F. IFN- $\gamma$  induces enhanced surface expression of MHC class I and II molecules on 1542-CP,TX. Untreated 1542-CP,TX cells

-6-

expressed a moderate amount of class I molecules (staining with mAb W6/32) (5A) but did not express detectable amounts of class II molecule (mAb L243) (5B). After exposure to IFN- $\gamma$  500 U/ml for 3 days, class I expression was enhanced (5C), and class II expression was induced (5D). MHC expression by autologous EBV-transformed B cells is shown for comparison (5E and 5F).

### **DETAILED DESCRIPTION OF THE INVENTION**

The present invention provides for the isolation, immortalization, and characterization of human adult prostate epithelial cell lines and clones derived from a number of fresh surgical specimens, including normal prostate and prostate cancer cell lines, and their potential applications in research and therapy.

The present invention generally provides immortal cell lines and clones of cell lines and pharmaceutical compositions comprising one or more of said cell lines, and their use as pharmaceutically active agents.

Specifically, the present invention provides cell lines of immortalized malignant adult prostate epithelial cell lines as well as matched autologous immortalized malignant and normal adult prostate epithelial cell lines. The immortalized prostate epithelial cell lines are herein designated as 1510-CP(carcinoma prostate), 1512-NP(normal prostate), 1512-CP, 1519-CP, 1532-NP (1532-NP, designated 1532-NPTX, has been deposited on February 2, 1996 with the American Type Culture Collection (ATCC) in 12301 Parklawn Drive, Rockville, Maryland under Accession No. CRL-12036), 1532-CP1, 1532-CP2 (1532-CP2, designated 1532-CP2TX, has been deposited on February 2, 1996 with the ATCC in Rockville, Maryland under Accession No. CRL-12038), 1535-NP (1535-NP, designated 1535-NPTX, has been deposited on February 2, 1996 in the ATCC in Rockville, Maryland under Accession No. CRL-12039), 1535-SV(seminal vesicle), 1535-CP1 (1535-CP1, designated 1535-CP1TX, has been deposited on February 2, 1996 with the ATCC in Rockville, Maryland under Accession No. CRL-12041), 1535-CP2, 1542-NP (1542-NP, designated 1542-NPTX, has been deposited on February 2, 1996 with the ATCC in Rockville, Maryland under Accession No. CRL-12040), 1542-SV, 1542-CP1, 1542-CP2, and



-7-

1542-CP3 (1542-CP3, designated 1542-CP3TX, has been deposited on February 2, 1996 with the ATCC in Rockville, Maryland under Accession No. CRL-12037).

5 The present invention also provides cloned, immortalized malignant prostate epithelial cell lines. Furthermore, the present invention also provides such clones characterized as having at least one allelic loss of heterozygosity (LOH).

10 In one embodiment, the cloned, immortalized, malignant, human, adult prostate epithelial cell line is characterized as having at least one allelic loss of heterozygosity. The loss of heterozygosity may occur on one or more chromosomes such as chromosome 1, 8, 10 and 16. In one embodiment, the cloned, immortalized, malignant, human, adult prostate epithelial cell line is characterized as having loss of heterozygosity at one or more loci on chromosome 8p. In a further embodiment, the cloned immortalized malignant prostate epithelial cell line has one or more allelic loss of heterozygosity at loci 12 through 21 on chromosome 8p.

15 In a particular embodiment, the cloned immortalized malignant, human, adult prostate epithelial cell line is characterized as having loss of the lower alleles of D8S133, D8S136 and D8S131. The cloned, immortalized cell line has the identifying characteristics of a cloned immortalized malignant, human, adult prostate epithelial cell line 1542-CP<sub>3</sub>TX.8.1 deposited as ATCC CRL-12265  
20 on January 15, 1997 with the American Type Culture Collection in Rockville, Maryland under the terms of the Budapest Treaty.

25 In another particular embodiment, the cloned, immortalized, malignant, human, adult prostate epithelial cell line is characterized as having loss of the upper alleles of D8S133, D8S136, and D8S131. The cloned, immortalized cell line has the identifying characteristics of a cloned, immortalized, malignant, human, adult prostate epithelial cell line 1542-CP<sub>3</sub>TX.8.4 deposited as ATCC CRL-12264 on January 15, 1997 with the American Type Culture Collection in Rockville, Maryland under the terms of the Budapest Treaty.

30 In another particular embodiment, the cloned, immortalized, malignant, human, adult prostate epithelial cell line is characterized as having loss of the lower alleles of SFTP-2, D8S136 and D8S131 and the upper alleles of D8S133 and NEFL. The cloned cell line has the identifying characteristics of a

-8-

cloned malignant prostate epithelial cell line 1535-CP,TX.14.3 deposited as ATCC CRL-12263 on January 15, 1997 with the American Type Culture Collection in Rockville, Maryland under the terms of the Budapest Treaty.

5 The cell lines and cloned cells of the present invention are immortalized using the human papillomavirus (HPV) gene or portion thereof. In one embodiment, the malignant cells are immortalized using the portion of HPV encoding E6 and E7 carried in a recombinant retrovirus. Cultures of the immortalized malignant prostate epithelial cells of the present invention remain stable and viable with continuous passage for over 1 year and longer.

10 The present invention also provides a method of isolating and cloning pure cell lines of human, adult prostate epithelial cells. Specifically, the method is effective in removing nonepithelial cells from the cultures, in particular in removing fibroblasts from the cultures. The method entails the careful dissection of fresh primary tumors into cells or tissues morphologically resembling  
15 the normal prostate gland and those resembling the malignant prostate. To prevent the growth of fibroblasts, cells are cultured in medium with little or no fetal bovine serum and/or cholera toxin. Differential trypsinization may also be used to eliminate fibroblasts from cultured prostate epithelial cells. The resulting epithelial cell lines are >90% pure, preferably 100% pure. Subsequent cloning of the cell  
20 lines results in cells which are 100% pure epithelial cells.

Another aspect of the present invention is a method of selecting for immortalized malignant prostate epithelial cells. The prior art has used markers such as PSA expression, PAP expresssion, PSA up-regulation by androgen, malignant growth in nude mice and aneuploid karyotypes as means of  
25 distinguishing malignant prostate epithelial cells from normal prostate epithelial cells. However, these markers do not consistently distinguish malignant prostate epithelial cells from normal cells. The present method of selecting for immortalized malignant prostate epithelial cells based on loss of heterozygosity provides a consistant, reproducible method of selection. The method employs at  
30 least one DNA marker that identifies a specific loss of allele on a particular chromosome. In one embodiment of the method, the DNA marker identifies a specific loss of allele on chromosome 8p. The method may use multiple DNA

-9-

markers to identify more than one loss of allele on a particular chromosome, or allelic loss on multiple chromosomes.

In the method of detecting and identifying malignant cells, PCR primers specific for distinct chromosomal loci are incubated with DNA isolated from an immortalized prostate epithelial cell line, and a PCR assay is conducted. The amplified products are analysed for LOH at one or more loci in comparison with a DNA control taken from known normal cells. One criterion for designating LOH is at least 75% loss of one allele by the malignant cell as compared to the normal DNA control, determined by visual inspection of autoradiographs. Other methods known to those practiced in the art, include densitometry analysis to detect differences, the criteria for designating LOH being at least 30% loss of one allele by the malignant cell.

The immortalized, malignant, prostate epithelial cell lines and clones of the present invention are useful in identifying novel genes unique to or overexpressed in malignant prostatic epithelial cells and which are not found or are not active in normal prostatic epithelial cells. The novel genes include but are not limited to transforming genes, growth factor genes, oncogenes, tumor suppressor genes. These genes may be identified using methods of RNA subtraction analysis known to those practiced in the art, such as standard subtractive hybridization, differential display, or representative differential analysis (RDA) (51, 52). The novel genes are cloned using standard molecular biology techniques as are known in the art. Identification of novel genes associated with the development of prostate cancer allows for the development of antisense oligonucleotides useful in inhibiting or preventing prostate cancer (42) and for the development of recombinant DNA vaccines.

The cell lines of the present invention are useful as models in epithelial cell oncogenesis studies. For example, the epithelial prostate cell lines of the present invention are particularly useful for understanding the tumorigenesis of prostate cancer. The present invention provides for a benign prostate cell line for use in combination with a malignant prostate cell line derived from the same patient as reagents for defining the genetic events leading from the benign to the

-10-

malignant cellular phenotype, and for investigating the role of heredity in prostate cancer.

The cell lines of the present invention can be utilized in a method of producing a preselected protein or portion thereof and a method of producing proteins of malignant, prostatic, epithelial cell origin. For example, the cell lines of the present invention are useful for the isolation of prostate cancer associated proteins which could serve as markers for diagnosis or targets for immunotherapy. In one embodiment of the invention, a method for the production of protein is provided comprising the steps of culturing the epithelial cell lines of the present invention and collecting one or more proteins produced by the novel cells. Identification of the genes encoding such protein, using standard scientific practice, enables construction of recombinant vectors and host cells for efficient large-scale production of the protein or portions thereof.

The present invention encompasses a novel recombinant virus expressing a prostate cancer-associate protein, or portion thereof. The recombinant virus may also express one or more costimulatory molecules, cytokines, MHC molecules, chemokines and the like for enhancing the immune response to the prostate cancer-associate protein or portion thereof. Method for constructing and expressing exogenous gene products from recombinant virus vectors are known in the art (43-50).

The present invention encompasses isolated DNA or RNA derived from immortalized human adult prostate epithelial cell lines or clones. Of interest is DNA or RNA isolated from immortalized human malignant adult prostate epithelial cells exhibiting LOH. Also of interest is DNA and RNA derived from matched autologous immortalized human normal and malignant adult prostate epithelial cells. The isolated DNA, RNA or oligonucleotides thereof may be used in the detection and diagnosis of prostate cancer or precancer in an individual. The DNA, RNA or oligonucleotides may be used as probes and/or primers in standard molecular biology methods such as Southern blot analysis, Northern blot analysis, PCR, RT-PCR and the like for detection and diagnosis of prostate cancer or precancer. Of interest is DNA, and the corresponding RNA, having loss of alleles on one or more chromosomes such as 1, 8, 10 and 16. Of particular interest is

-11-

DNA, and the corresponding RNA, having loss of one or more alleles on chromosome 8.

Naked DNA encoding prostate cancer antigen or epitopes thereof may be used for active immunotherapy against prostate cancer. Techniques known in the art may be used to inject the naked DNA or naked DNA linked to lipids into muscle or skin to elicit both a cellular and humoral immune response to the encoded prostate cancer antigen or epitopes thereof (33-41).

The cell lines of the present invention are also useful for testing the effects of therapeutic agents against prostate cancer in vivo or in vitro. For example, chemotherapeutic drugs, biologic response modifiers, or genetic reagents such as anti-sense oligonucleotides may be screened for efficacy. The chemical or agent to be tested is placed in the presence of the cells *in vivo* or *in vitro*. After a suitable period of exposure, the effect of the chemical or agent on the cell is assessed by methods known in the art such as cytotoxicity assay, protein inhibition assays, inhibition of tumor growth and the like. A chemical or agent that inhibits a vital metabolic function or kills the cells is considered an effective therapeutic agent.

The cell lines and clones of the present invention are also useful as a whole cell vaccine for treating or preventing the recurrence of prostate cancer. The whole cell vaccine may be administered in the native form, in combination with adjuvants, or as modified by transgenes encoding, for example, various cytokines, chemokines, costimulatory molecules, adhesion molecules, MHC molecules and the like. Such modifications may be used to enhance the immunotherapeutic effect of the immunogen and vaccine of the present invention.

The genes may be incorporated into the immortalized human malignant prostatic epithelial cell lines and clones by methods known in the art such as electroporation, polybrene-induced DNA transfection, via plasmids, via recombinant virus, and the like. Recombinant virus containing one or more genes of interest may be constructed as described in WO94/16716, WO96/11279 and WO96/10419.

-12-

Costimulatory molecules which may be employed in the present invention include but are not limited to B7-1, B7-2, B7-3, ICAM-1, LFA-1, LFA-3, CD72 and the like.

5 Cytokines which may be utilized in the present invention include but are not limited to IL-2, GM-CSF,  $\text{TNF}\alpha$ ,  $\text{IFN}\gamma$ , IL-12, IL-4, IL-7, and the like.

MHC molecules include but are not limited to class I or class II molecules and the like. Nonclassical MHC molecules or MHC-like molecules such as CD1 may also be used.

10 Chemokines include but are not limited to RANTES, IL-8, MIP1-alpha, MIP1-beta, and the like.

The cell lines of the present invention are also therapeutically useful as stimulants for raising prostate cancer-reactive antibodies or immune cells from peripheral blood or lymph node cells for administration to prostate cancer patients.

15 The present invention also provides for immortal prostate cell lines for use in molecular cloning of prostate cancer-associated antigens recognized by the immune system. These antigens are then developed into recombinant vaccines directed to the prevention or cure of prostate cancer.

20 The present invention further provides for pharmaceutical compositions comprising the immortal cell lines of the present invention, and for pharmacological, therapeutic and diagnostic uses for the immortal cell lines and pharmacological compositions comprising the same.

25 Pharmaceutical compositions, vaccines and immunogens can be prepared in accordance with standard techniques known to those skilled in the pharmaceutical art. Such compositions can be administered to a patient in need of such administration in dosages and by techniques known to those skilled in the art taking into consideration such factors as the age, weight and condition of the particular patient, and the route of administration.

30 The immunization protocol for the compositions, vaccines and immunogens may be via a parenteral route (intravenous, intraperitoneal, intradermal, intramuscular or subcutaneous). The composition, vaccine and immunogen may be administered directly into a tumor mass. Moreover, the

-13-

compositions may be used *in vitro* to stimulate antigen specific cytotoxic T lymphocytes which are then administered back to the patient.

5 The compositions, vaccines and immunogens may be coadministered or sequentially administered with adjuvants, such as alum, incomplete Freund's adjuvant and the like, cytokines, costimulatory molecules, chemokines, adhesion molecules, MHC molecules and the like. Additionally, the compositions, vaccines and immunogens may be coadministered or sequentially administered with anti-neoplastic, antitumor, anticancer agents and/or with agents which reduce or alleviate ill effects of antineoplastic, antitumor or anticancer agents.

10 Examples of vaccines or compositions of the invention include liquid preparations such as suspension, syrups, elixirs and preparations for parenteral, subcutaneous, intradermal, intramuscular or intravenous administration. The pharmaceutical compositions may be in admixture with a suitable carrier, diluent or excipient such as sterile water, physiological saline, glucose and the like.

15 The efficacy of the treatment can be assessed by production of antibody or immune cells that recognize the malignant cell or prostate cancer peptide or portion thereof, assessment of antigen specific cytotoxicity, specific cytokine production or tumor regression.

20 The immortalized, human adult prostate epithelial cells or portions thereof may be provided in the form of a kit. The kit may include one or more immortalized, human, adult prostate epithelial cells or portions thereof. Portions encompass lysed cells, cell fragments, intracellular contents, extracellular components, protein, DNA, RNA, glycolipids and the like. Kits may also include autologous immortalized, human adult malignant prostate epithelial cells or portions thereof in combination with autologous immortalized, human adult normal prostate epithelial cells or portions thereof. In one embodiment, the kit comprises the immortalized, human adult normal epithelial cell line, 1532-NP in combination with the autologous, immortalized, human, adult, malignant cell line 1532-CP1 and/or 1532-CP2. In another embodiment, the kit comprises the immortalized, human, adult, normal epithelial cell line, 1535-NP in combination with the autologous immortalized human, adult, malignant cell line 1535-CP1, 1535-CP2 and/or 1535-CP1TX.14.3. In yet another embodiment the kit comprises the

25

30

-14-

immortalized, human, adult normal epithelial cell line, 1542-NP in combination with one or more of the autologous immortalized human, adult malignant cell lines 1542-CP1, 1542-CP2, 1542-CP3, 1542-CP,TX.8.1 and 1542-CP,TX.8.4. The kit may include a separate container containing a suitable carrier, diluent or excipient.

5 The kit may also include an adjuvant, cytokine, costimulatory molecule, chemokine, adhesion molecule, MHC molecule, antineoplastic agent, antitumor agent, immunoassay reagents, PCR reagents, radiolabels and the like. Additionally, the kit may include instructions for mixing or combining ingredients and/or administration.

10 The term "immortalized" as used herein means that the cell line grows continually without senescence when cultured in vitro in a suitable growth medium.

The present invention also encompasses polyclonal and monoclonal antibodies directed to the cell lines of this invention. These antibodies can then be  
15 used to prepare antibody containing compositions used in the methods of the present invention. The antibodies are prepared via techniques well known to those having ordinary skill in the art. In particular, monoclonal antibodies produced against the immortal prostate cell lines of the present invention are useful in the detection and therapy of prostate cancer. The antibody or antigen binding portion  
20 thereof binds to malignant prostate cells. The antibody or antigen binding portion thereof is immunoreactive with at least one prostate tumor rejection antigen or with at least one prostate cancer-associated antigens and epitopes thereof.

Exemplary antibody molecules are intact immunoglobulin molecules, substantially intact immunoglobulin molecules or those portions of an  
25 immunoglobulin molecule that contain the antigen binding site, including F(ab), F(ab)<sub>2</sub>, and F(v). Polyclonal or monoclonal antibodies may be produced by methods known in the art. (Kohler and Milstein, 1975 Nature 256:495-497; Campbell "Monoclonal Antibody Technology, the Production and Characterization of Rodent and Human Hybridomas" in Burdon et al (eds) (1985), "Laboratory  
30 Techniques in Biochemistry and Molecular Biology", Vol. 13, Elsevier Science Publishers, Amsterdam). The antibodies or portions thereof may also be produced by genetic engineering including chimeric antibody, single chain antibody as



-15-

described in Traunecker et al The EMBO J. 10 (2):3655-3659, 1991 and Milenic, D.E. et al Cancer Research 51, 6363-6371, 1991 and humanized antibody as described in U.S. Patent No. 5,530,101.

5 The antibody or portion thereof may be used as an immunotherapeutic. The antibody or portion thereof may be administered alone, or in combination with chemotherapeutics or immunosuppressive agents as are known in the art.

10 The antibody or portion thereof may also be used as an immunotoxin to specifically target and kill malignant prostatic cells. Immunotoxins are characterized by two components and are particularly useful for killing selected cells *in vitro* or *in vivo*. One component is a cytotoxic agent which is usually fatal to a cell when attached or absorbed. The second component, known as the delivery vehicle, provides a means for delivering the toxic agent to a particular cell type, such as malignant prostate cells. The two components are commonly bonded  
15 together by any of a variety of well-known chemical procedures. For example, when the cytotoxic agent is a protein, the linkage to the antibody may be by way of hetero-bifunctional crosslinkers, e.g., SPDP, carbodiimide, glutaraldehyde, and the like. Production of various immunotoxins is well-known in the art, for example in "Monoclonal Antibody-Toxin Conjugates: Aiming the Magic Bullet", Thorpe et al,  
20 Monoclonal Antibodies in Clinical Medicine, Academic Press, pp. 168-190 (1982). The components may also be linked genetically as described in Chaudhary et al Nature 339, 394 (1989).

A variety of cytotoxic agents are suitable for use in immunotoxins. Cytotoxic agents include but are not limited to radionuclides, such as Iodine-131 or  
25 other isotopes of iodine, Yttrium-90, Rhenium-188, and Bismuth-212 or other alpha emitters; a number of chemotherapeutic drugs, such as vindesine, methotrexate, adriamycin, taxol, and cisplatinum; and cytotoxic proteins such as ribosomal inhibiting proteins like pokeweed antiviral protein, *Pseudomonas* exotoxin A, ricin, diphtheria toxin, ricin A chain and the like (see "Chimeric  
30 Toxins", Olsnes and Phil, Pharmac. Ther. 25, 355-381 (1982), and "Monoclonal Antibodies for Cancer Detection and Therapy", eds. Baldwin and Byers, pp. 159-179, 224-266, Academic Press, 1985).

-16-

For diagnostic purposes, the antibody may be either labeled or unlabeled. Unlabeled antibody may be used in combination with other labeled antibodies. A wide variety of labels may be employed, such as radionuclides, fluors, enzymes, enzyme substrates, enzyme cofactors, enzyme inhibitors, ligands and the like. Numerous types of immunoassays are available and are well-known to those skilled in the art.

The cell lines, genes, proteins, and antibodies of the present invention are useful in a variety of therapeutic and diagnostic settings. These are described with more specificity below.

The references disclosed are incorporated herein by reference.

#### Example I

*(1) Characteristics of patients from whom cultured epithelial cell lines were initiated.*

Prostate epithelial cell lines were initiated from radical prostatectomy specimens from 6 consecutive patients with intermediate to high grade tumors (Gleason grades 6-8). (See Table 1). Cell cultures were initiated by mechanical disruption or enzymatic digestion of primary tumor nodules excised from fresh radical prostatectomy specimens. See Example II for detailed description of culture methods.

**Table 1: Prostate Cancer Patients: Clinical Information**

Patient #	Age(yrs)	Pre-Op PSA (ng/ml)	Post-Op Gleason Grade
1510	51	14.9	3 + 3 = 6
1512	64	14.0	4 + 3 = 7
1519	54	7.7	4 + 4 = 8
1532	52	5.0	3 + 3 = 6
1535	66	2.2	3 + 5 = 8
1542	48	14.3	3 + 5 = 8

-17-

***(2) Pathological analysis of tissue specimens.***

Pathological analysis of fresh tissue specimens used to initiate prostate cancer cell lines revealed that some cancer specimens were pure tumor, while others consisted of mixtures of benign and malignant cells. See Table 2:

- 5 Preliminary identification of specimens was assigned on gross examination by an experienced pathologist. Microscopic identification was assigned on examination of 10 high power fields by an experienced pathologist. BPH = benign prostatic hypertrophy. PIN = prostatic intraepithelial neoplasia. \* = a mixture of cell types. † = 80% of specimen consisted of benign fibromuscular stroma. ° = one
- 10 microscopic focus of cancer noted.

Table 2: Pathologic Analysis of Fresh Prostate Specimens

Patient #	Gross Specimen	Microscopic Analysis (estimate % total cells)			
		Benign	BPH	PIN	Tumor
1510	Tumor	40 <sup>a</sup>	0	40 <sup>a</sup>	60
1512	Normal Prostate	100	0	0	0
	Tumor	90 <sup>a</sup>	90 <sup>a</sup>	0	10
1519	Normal Prostate	100	0	0	0
	Tumor	50	0	0	50
1532	Normal Prostate	95	0	5	0
	Tumor 1	100	0	0	0
	Tumor 2	0	0	0	100
1535	Normal Prostate	20 <sup>b</sup>	0	0	0
	Seminal Vesicle	100	0	0	0
	Tumor 1	0	0	0	100
	Tumor 2	5	0	10	85
1542	Normal Prostate	0	95	5	— <sup>c</sup>
	Seminal Vesicle	100	0	0	0
	Tumor 1	0	0	40	60
	Tumor 2	0	0	40	60
	Tumor 3	0	0	40	60

(3) Confirmation of epithelial origin of prostate-derived cell lines.

The epithelial origin of prostate-derived cell lines was confirmed with cytokeratin staining. Both high and low molecular weight cytokeratins were expressed by all 16 cell lines generated from 6 radical prostatectomy specimens (normal prostate, prostate cancer, normal seminal vesicle). With the exception of an early passage of 1519-CP, none of the prostate-derived cell lines expressed PSA or PAP. See Table 3: F = fibroblasts, NP = normal prostate, SV = seminal vesicle, CP = carcinoma prostate. <sup>a</sup> = includes both high and low molecular weight keratins. <sup>b</sup> = PSA and PAP expression was noted at culture passage number 5 but was lost after continued passage in vitro. <sup>c</sup> = observed staining was noted as possible background.

**Table 3: Immunocytochemical Analysis of Immortalized Prostate Epithelial Cell Lines**

Patient #	Cell Source	% Positive Cells (stain intensity)		
		PSA	PAP	Cytokeratin <sup>a</sup>
1510	F	0	0	25(1-2+) <sup>c</sup>
	CP	0	0	> 75(4+)
1512	NP	0	0	> 75(4+)
	CP	0	0	> 75(4+)
1519	F	0	0	> 75(1+) <sup>c</sup>
	CP	> 75(2-3+) <sup>b</sup>	> 75(4+) <sup>b</sup>	> 75(4+)
1532	F	0	0	5(1-2+)
	NP	0	0	> 75(4+)
	CP1	0	0	> 75(4+)
	CP2	0	0	> 75(4+)
1535	NP	0	0	> 75(4+)
	SV	0	0	> 75(4+)
	CP1	0	0	> 75(4+)
	CP2	0	0	> 75(4+)
1542	NP	0	0	> 75(4+)

-20-

Patient #	Cell Source	% Positive Cells (stain intensity)		
	SV	0	0	> 75(4+)
	CP1	0	0	> 75(4+)
	CP2	0	0	> 75(4+)
	CP3	0	0	> 75(4+)
5 LNCaP		> 75(4+)	25(3-4+)	> 75(4+)

**(4) Cell surface phenotyping.**

Cell surface phenotyping is described in Example II, Table 6.

**(5) Genetic Analysis of Prostate Epithelial Cell Lines.**

10 Allelic loss on chromosome 8 has been associated with PIN and  
invasive prostate cancer, and thus represents an alternative method for  
characterizing epithelial cell lines derived from prostate cancer specimens.  
Examination of allelic loss at 10 separate loci on chromosome 8p using PCR  
(polymerase chain reaction) revealed loss of heterozygosity (LOH) at one locus in  
15 1 of 9 uncloned cancer-derived cell lines examined, suggesting that this is an  
established long-term primary prostate tumor cell line. Although extreme care was  
taken to dissect the purest tumor fragments possible for in vitro cultivation,  
subsequent microscopic evaluation of the original tumor specimens exhibited a  
variable mixture of benign epithelium, BPH, PIN, and/or invasive tumor (see  
20 Table 2) which could mask LOH, making epithelial cell cloning necessary for  
precise characterization. Definitive genetic characterization of the prostate  
epithelial cell cultures described herein, and single cell cloning of said lines, are  
described below.

-21-

Example II

Single Cell Cloning and Characterization of  
Immortalized Malignant Prostatic Epithelial Cells

5

**Materials and Methods**

**Initiation of Primary Cell Cultures.** Tissue specimens used for generating cell lines were obtained from six consecutive patients under going radical prostatectomies at the NCI for treatment of intermediate to high grade localized prostate cancer (Gleason grades 6 - 8, tumor stages T2C to T3C). Fresh prostatectomy specimens obtained directly from the operating room were dissected under sterile conditions by an experienced pathologist. Tissues designated as normal prostate, prostate cancer, or normal seminal vesicle on gross inspection were dissected separately for the purpose of generating cell cultures. Cultures were initiated by mechanical disruption (< 1 cm diameter fragments) or enzymatic digestion (> 1 cm fragments) (21). Specimens from patients 1510 and 1512 were prepared by enzymatic digestion, while subsequent cultures were initiated by mechanical disruption. For enzymatic digestion, minced tissue was suspended in 100 ml of digestion media and left on a stir plate overnight at room temperature. The resulting single cell suspension was then washed with sterile PBS, resuspended in growth medium (see below) and dispensed into 6-well plates coated with type I rat tail collagen (Collaborative Biomedical Products, Bedford, MA). For mechanical disruption of specimens, tissue fragments were carefully minced into 2-3 mm cubes in a small volume of growth medium, and the resultant slurry of tissue and cells was dispensed into 6-well plates. All cultures were initiated in a volume of 1 ml per well and incubated at 37° C, 5% CO<sub>2</sub>. They were not disturbed for 2 - 3 days to allow viable cells and tissue chunks to settle and attach to the plates. Then, the unattached debris was carefully aspirated, and wells were refed with 3 - 5 ml fresh medium. Culture medium was routinely replaced every 2-4 days and proliferating adherent cells were passaged following detachment with trypsin. Established growing cultures were maintained in tissue culture flasks (Falcon, Becton Dickinson, Lincoln Park, NJ). Growth medium for prostate and

-22-

seminal vesicle epithelial cell-lines consisted of keratinocyte serum free medium (Keratinocyte-SFM. GIBCO-BRL, Grand Island, NY) containing 25  $\mu$ g/ml bovine pituitary extract, 5 ng/ml epidermal growth factor, 2 mM L-glutamine, 10 mM HEPES buffer, antibiotics and 5% heat- inactivated fetal bovine serum (FBS) (Biofluids, Rockville, MD). For the initiation of epithelial cultures from fresh tissue specimens, the concentration of FBS was reduced to 1-2% and/or cholera toxin (Sigma, St. Louis, MO) was added at 10 - 20 ng/ml to guard against outgrowth of contaminating fibroblasts. In the rare event that fibroblasts persisted in epithelial cell cultures, differential trypsinization (incubation for 1 - 2 min at 37° C, followed by washing away detached fibroblasts to leave the more adherent epithelial cells) was extremely successful in achieving pure epithelial cell cultures.

Autologous fibroblast cell lines were generated from mechanically disrupted benign prostate stromal tissue and cultured in RPMI 1640 medium containing 10% heat-inactivated FBS. Autologous Epstein-Barr virus-transformed B cell lines were generated using standard techniques and cultured in RPMI 1640 + 10% FBS.

**Metastatic Prostate Cancer Cell Cultures.** The adherent cell lines LNCaP, DU145, PC-3 (ATCC, CRL1740, HTB 81, CRL1435, respectively) and TSU-Prl (kindly provided by Dr. William Isaacs, Johns Hopkins University, Baltimore, MD; as described in Iizumi et al, *J. Urol.* 137:1304-1306, 1987) were maintained in RPMI 1640 medium supplemented with 10% FBS.

**Immortalization of Primary Cell Cultures.** Cell culture immortalization was accomplished by transduction of actively proliferating cells with a recombinant retrovirus encoding the E6 and E7 transforming proteins of human papillomavirus serotype 16 (HPV16) and the eukaryotic selection marker neomycin phosphotransferase, designated LXSNI6E6E7 (generously provided by Dr. Denise Galloway, Fred Hutchinson Cancer Research Center, Seattle, WA) (22). In preparation for immortalization, short-term epithelial cell cultures (culture passage 1 - 3) were split 1:2 and allowed to reattach in 6-well plates for at least 48 h, yielding cultures which were 50-60% confluent. Transduction with the LXSNI6E6E7 retrovirus was accomplished by replacing the culture medium with



-23-

culture supernatant collected from the retrovirus producer line PA317 (22), in the presence of 10  $\mu\text{g/ml}$  DEAE-dextran (Sigma), for a period of 24 h.

**Single Cell Cloning of Immortalized Cell Cultures.** Clonal populations of immortal epithelial cell cultures were generated for use in LOH characterization studies. Briefly, confluent cell cultures were harvested with trypsin, washed and counted. Cells were serially diluted to a concentration of 2-5 cells /ml in keratinocyte growth medium (see above) and dispensed into 8-10 individual 96 well flat bottom microculture plates at 200  $\mu\text{l/}$  well ( $\leq 1$  cell/well). Confluent wells originating from dilutions of  $< 1$  cell/ well were expanded to 24 well plates to ensure enough cells for DNA extraction and cryopreservation

**Immunocytochemical Analysis.** For immunocytochemical studies of immortalized cultured cells, cells were harvested with trypsin, washed and pelleted. Cell pellets were subsequently fixed in 10% buffered formalin and embedded in paraffin. Fresh tissue sections from prostate specimens were also fixed in formalin and paraffin-embedded. Five micron sections were prepared from fresh tumor specimens and cultured cell blocks and mounted on charged slides (Fisher Scientific, Pittsburgh, PA) (23). Immunocytochemistry was performed using the avidin-biotin peroxidase complex method and the following primary antibodies: monoclonal anti-human prostate specific antigen (PSA) (Dako Corp, Carpinteria, CA); polyclonal anti-human prostatic acid phosphatase (PAP) (Dako Corp, Carpinteria, CA); anti-human cytokeratin CAM 5.2 (Becton-Dickinson, San Jose, CA); and anti-human cytokeratin AE1/AE3 (Boehringer-Mannheim, Indianapolis, IN). Cell lines and tumor tissue sections were evaluated based on the percentage of cells staining ( $< 25\%$ ,  $25-50\%$ ,  $50-75\%$  or  $> 75\%$ ) as well as staining intensity (1+ to 4+).

**Flow Cytometry.** For future studies and further characterization, it was of interest to determine the extent of expression of surface molecules of immunologic importance on the long-term prostate epithelial cell lines. Immortalized cell cultures were harvested and stained with the following monoclonal antibodies: CD54 (anti-ICAM-1), CD80 (anti-B7.1), CD86 (anti-B7.2) (Becton-Dickinson), W6/32 (anti-HLA-A,B,C) and L243 (anti-HLA-DR) (ATCC, Rockville, MD) (21). To enhance surface expression of MHC molecules, cells

-24-

were cultured in the presence of IFN- $\gamma$  500 U/ml for 72 h prior to flow cytometric analysis.

**Microdissection and DNA Extraction.** Microdissection of selected foci of normal prostate epithelial cells or invasive tumor cells from formalin-fixed, paraffin-embedded tissue samples was performed under direct light microscopic visualization as described previously (24,25,26). Briefly, unstained formalin-fixed, paraffin-embedded 5 micron histologic tissue sections were prepared on glass slides and deparaffinized twice with xylene, rinsed twice with 95% ethanol, stained with eosin and air-dried. The adjacent section was stained with hematoxylin and eosin. Specific cells of interest were selected from the eosin stained slides and microdissected using a disposable, modified 30 gauge needle. DNA was extracted from 1 - 5 X 10<sup>3</sup> cells procured by microdissection. In some cases, cells from more than one dissected adjacent tubule of cancer or normal epithelium were combined. DNA was also extracted from 1 - 5 X 10<sup>4</sup> cells obtained from actively growing immortalized cultures. Cells were immediately resuspended in a solution (20  $\mu$ l for microdissected or 200  $\mu$ l for cultured cells) containing 0.01 M TRIS-HCl pH8.0, 1 mM EDTA, 1% Tween 20, and 0.1 mg/ml proteinase K, and incubated overnight at 37°C. Following incubation, the mixture was boiled for 5-10 min to inactivate the proteinase K and stored at 4°C for subsequent polymerase chain reaction (PCR) analysis.

**Detection of Loss of Heterozygosity.** The polymorphic DNA markers studied for the detection of LOH on chromosome 8p12-21 included: SFTP-2, D8S133, D8S136, NEFL, D8S137, D8S131, D8S339 and ANK. The PCR primer pairs used to amplify the DNA microsatellite markers is as follows:

1)SFTP2

Nucleic Acid Sequences: L16861

Primers:	Primer Name	Primer Sequence
	SFTP2CA	CAGCCAGACAGGCTGGAA (Seq. ID No. 1)
	SFTP2GT	ACTTTTCTGGCCAAACTCCTG (Seq. ID No. 2)

Amplified Seq Min Length: 0.111

Amplified Seq Max Length: 0.157

-25-

as described in Wood, S. Genomics 24:597-600, 1994. SFTP2 maps in the region between 8p11 - 8p22.

## 2)D8S133

5

Nucleic Acid Sequences: M73471

Primers:      Primer Name   Primer Sequence

10

D8S133CA	CAGGTGGGAAAAGTGGGGA (Seq. ID No. 3)
D8S133GT	AGCAACTGTCAACATATTGCTC (Seq. ID No. 4)

Amplified Seq Min Length: 0.094

Amplified Seq Max Length: 0.112

15

as described in Wood, S. Cytogenet Cell Genet 58:1932, 1991; Wood, S. Genomics 13:232, 1992.

## 3)D8S136

20

Primers:      Primer Name   Primer Sequence

D8S136CA	GCCCAAAGAGGAGAATAAA (Seq. ID No. 5)
D8S136GT	CTGTTTCCACACCGAAGC (Seq. ID No. 6)

25

Amplified Seq Min Length: 0.071

Amplified Seq Max Length: 0.089

as described in Wood, S. Cytogenet Cell Genet 58:1932, 1991.

30

## 4)NEFL

Nucleic Acid Sequences: L04147

35

Primers:      Primer Name   Primer Sequence

214	GCAGTAGTGCCGCAGTTTCA (Seq. ID No. 7)
215	TGCAATTCATCTTCCTTTCT (Seq. ID No. 8)

40

Amplified Seq Min Length: 0.137

Amplified Seq Max Length: 0.147

as described in Rogaev, E. Hum. Mol. Genet. 1:781, 1992.

45

## 5)D8S137

-26-

## Nucleic Acid Sequences: X61694

## Primers: Primer Name Primer Sequence

5 D8S137CA AAATACCGAGACTCACACTATA (Seq. ID No. 9)  
D8S137GT GCTAATCAGGGAATCACCCAA (Seq. ID No. 10)

Amplified Seq Min Length: 0.152

Amplified Seq Max Length: 0.161

10

as described in Wood, S. Cytogenet Cell Genet 58:1932, 1991; Wood, S. Nucleic Acids Res. 19:6664, 1991.

15 6)D8S131

## Primers: Primer Name Primer Sequence

20 131CA2-1 ACATAGGCTGGAGAGTCACAGG (Seq. ID No. 11)  
131CA2-2 GGATGAGGCTCAGCACACAAGC (Seq. ID No. 12)

Amplified Seq Min Length: 0.132

25 Amplified Seq Max Length: 0.144

as described in citations: Yu, CE Hum. Mol. Genet. 3:211, 1994.

30 7)D8S339

## Primers: Primer Name Primer Sequence

35 WT251-A TAGATGTTACCATTTTCAC (Seq. ID No. 13)  
WT251-B GATTAGATCTTGGATCAG (Seq. ID No. 14)

Amplified Seq Min Length: 0.162

Amplified Seq Max Length: 0.176

40 as described in citations: Thomas, W. Hum. Mol. Genet. 2:828, 1993.

8)Ank

45 Nucleic Acid Sequences: D16990

## Primers: Primer Name Primer Sequence

-27-

ANK1.PCR1.1 TCCCAGATCGCTCTACATGA (Seq. ID No. 15)  
ANK1.PCR1.2 CACAGCTTCAGAAGTCACAG (Seq. ID No. 16)

as described in Polymeropoulos et al Nucleic Acids Res 19:969, 1991.

5

PCR was performed as previously described (19). Briefly, 12.5ul PCR reaction mixtures contained 200  $\mu$ M dATP, dGTP and dTTP; 40  $\mu$ M dCTP; 0.8 mM primers (Research Genetics, Huntsville, Ala., or synthesized on an Applied Biosystems DNA synthesizer); 2  $\mu$ Ci [ $\alpha^{32}$ P] dCTP; 16  $\mu$ M tetramethylammonium chloride (27); 1X PCR reaction buffer (containing 1.25 mM MgCl<sub>2</sub>) and 1 unit of Taq polymerase (Boehringer Mannheim). Five percent DMSO was added to reactions for markers D8S133 and D8S137 to improve amplification and resolution of the products. Reactions with all markers were performed as follows: 2 min at 95°C, followed by 28 to 40 cycles (depending on the marker) of annealing and extension (95°C for 30 sec, annealing temp. for 30 sec, and 72°C for 30 sec) and a 2 min incubation at 72°C. Annealing temperatures for each marker were determined empirically after an initial estimate based on primer length and composition.

10

15

The labeled amplified DNA samples were denatured for 5-10 min at 90°C and loaded onto a gel consisting of 7% acrylamide (30:0.8 acrylamide: bisacrylamide), 5.6 M urea, 32% formamide and 1X TBE (0.089 M Tris pH 8.3, 0.089 M borate, 0.002 M EDTA) (28). Samples were electrophoresed at 95 for 2-4 h. Gels were then transferred to sequencing gel filter paper (Bio-Rad), and autoradiography was performed with Kodak X-OMAT film. The criterion for LOH was at least 75% loss of one allele compared with an autologous fresh PBL control, as determined by direct visualization by three independent investigators. When sufficient DNA was available, LOH was verified with at least two independent experiments.

20

25

30

## Results

**Tissue Procurement for Cell Culture.** Being aware of the historical difficulties associated with generating immortal prostate cancer cell lines from primary (nonmetastatic) specimens, the largest grossly apparent tumor nodules (1 -

-28-

3 cm diameter) were initially selected as the fresh tissue source for generating cultures. Subsequent microscopic analysis of the neighboring tissue sections from the first three attempts (patients 1510, 1512, and 1519) revealed that "tumor" specimens actually contained a variable mixture of benign prostatic epithelium, benign prostatic hypertrophy (BPH), prostatic intraepithelial neoplasia (PIN) and invasive tumor cells. However, "normal" specimens from patients 1512 and 1519 consisted entirely of benign prostatic epithelium (Table 2).

To increase the likelihood of obtaining pure tumor tissue for starting tumor cell lines from subsequent patients, smaller tissue fragments (< 1 cm) were procured with neighboring sections designated for tissue culture, frozen and paraffin sections. In addition, whenever possible, multiple distinct tumor tissue fragments were selected from individual specimens for culture initiation. By employing these more stringent conditions it was possible to obtain tissue sections containing at least 95% neoplastic cells (PIN plus invasive cancer) in 6 of 7 attempts on three radical prostatectomy specimens (patients 1532, 1535, and 1542). In addition, tissue fragments suitable for initiating three benign prostate epithelial cell lines and two benign seminal vesicle epithelial cell lines were successfully dissected from these radical prostatectomy specimens (Table 2).

**Immortalization and Immunocytochemical Characterization of Prostate-Derived Cell Lines.** All but one of the 17 tissue specimens listed in Table 2 (normal prostate from patient 1519) was readily established in short-term culture. However, cell proliferation was relatively slow, and *in vitro* immortalization of epithelial cell cultures was necessary to establish actively growing cultures capable of surviving beyond 5 - 6 weeks. Adherent monolayer cultures were transduced at the second or third passage with a recombinant retrovirus encoding the E6 and E7 transforming proteins of HPV16, resulting in the establishment of 16 long-term epithelial cell lines: 4 derived from normal prostate, 2 from seminal vesicle and ten from primary tumor specimens. In addition, immortal fibroblast lines initiated from prostatic stroma in four patients were established. Successful transduction was confirmed by cell survival in G418 at a concentration of 1 mg/ml and extended cell viability and rapid proliferation beyond 50 culture passages when compared to non-immortalized cells cultured in parallel (Figure 1A) Microscopically, all

-29-

immortalized prostate epithelial cell lines exhibited a similar morphology whether derived from benign or malignant tissue, thus culture morphology was not a useful criterion for distinguishing benign from malignant cells (Figure 1B).

To confirm the epithelial and prostatic origins of the prostate-derived cell lines, immunocytochemistry was performed on cell blocks from actively growing immortalized cultures (Table 3). Both high and low molecular weight cytokeratins were expressed by all of the epithelial cell lines initiated in our laboratory, including those derived from normal prostate, normal seminal vesicle, and prostate cancer specimens. Greater than 75% of cells stained with 4+ intensity, similar to staining observed with the established metastatic prostate cancer cell lines LNCaP, DU145, PC-3 and TSU-Pr1. Thus, the epithelial origin of these cultures was confirmed. No significant cytokeratin expression was observed for control fibroblast lines or melanoma cells.

Although positive cytokeratin expression indicated that cell lines generated from primary prostate cancer specimens were in fact epithelial in origin, it was also of interest to assess expression of the prostate-associated proteins, PSA and PAP by these cultures. Only the immortalized prostate tumor-derived cell line generated from patient 1519 (1519-CPTX) expressed detectable levels of these proteins (> 75% of cells staining with 2 - 3 + intensity, and > 75% with 4 + intensity, respectively) following 5 culture passages. However, after 30 culture passages expression of PSA and PAP was no longer detectable in 1519-CPTX. Furthermore, expression was not inducible in late passages of this cell line by IFN-5-aza-2'-deoxycytidine or dihydroxytestosterone. Immunohistochemical examination of fixed prostate cancer tissue sections for the expression of PSA and PAP often showed weak and heterogenous staining of tumor coals, with some tumor foci demonstrating no detectable expression of these proteins. In contrast, all normal glands in the same microscopic sections stained strongly and uniformly for PSA and PAP (Figure 2). The weak, heterogenous expression of PSA and PAP by prostate cancer cells *in situ* may explain the absence of expression in the immortalized prostate tumor-derived cell lines. However, lack of expression in the benign prostate epithelial cell lines does not correlate with the strong expression

-30-

observed in the corresponding tissue sections, indicating that loss of PSA and PAP expression may also occur as a consequence of *in vitro* cell culture.

**Examination of Chromosome 8p for LOH in Microdissected Tissues.** As noted above, our "prostate cancer" cell lines were in most cases  
5 actually derived from tissue samples containing a mixture of benign and malignant cell types (Table 2). Since all cultures required retroviral transformation to induce long-term proliferation, and since benign and malignant transformed prostatic epithelial cells were indistinguishable on morphologic and histochemical grounds, the use of LOH analysis was investigated as an alternative means of characterizing  
10 the newly-established cultures. LOH on chromosome 8p 12-21 was first assessed in microdissected foci of tumor or normal epithelial cells from the corresponding fresh tissue sections. A panel of 8 microsatellite markers, previously shown to detect a high percentage of LOH in microdissected prostate cancer specimens (19), was selected to identify chromosome 8p deletions. The panel of eight  
15 microsatellite markers are capable of identifying deletions in loci 11 through 21 of chromosome 8 as depicted in Figure 3. Hypothesizing that microscopically normal-appearing cells might contain LOH as a precursor to malignant transformation, cryopreserved fresh autologous PBL were used as the normal control for LOH analysis. All 6 patients proved to be heterozygous (informative) at  
20 4 or more of the 8 loci examined upon analysis of DNA from fresh PBL. However, for 2 patients (1519 and 1532), microdissected tumor specimens did not yield evidence of LOH, indicating that LOH analysis might not be useful in characterizing cell cultures derived from those specimens (Table 4).



-31-

Table 4 LOH on chromosome 8p in Microdissected Foci of Prostate Cancer or Benign Epithelium

		Chromosome 8p Locus									
	Patient	No. of Foci Tested	SFTP-2	D8S133	D8S136	NEFL	D8S137	D8S131	D8S339	ANK	
5	1510 tumor	2	●	●	●	-	●	-	●		
	normal	3	●	●	●	-	●	-	●	●	
10	1512 tumor	1	-	●	●	●	nd	-	●	nd	
	normal	1	-	○	○	○	nd	-	○	nd	
15	1519 tumor	1	-	○	○	○	-	○	○	○	
	normal	1	-	○	○	○	-	○	○	○	
	1532 tumor	8	-	○	○	○	nd	-	○	nd	
	normal	1	-	○	○	○	nd	-	○	nd	
20	1535 tumor	6	●	●	●	●	-	●	○	-	
	normal	1	○	○	○	○	-	○	○	-	
25	Retention of heterozygosity (○)										
	Loss of heterozygosity (●)										
	Not informative (Homozygous alleles) (-)										
	Not determined (nd)										

In contrast, microdissected tumors from patients 1510 and 1512 demonstrated LOH at all examined informative loci. For patient 1535, 6 distinct microdissected foci of tumor were examined and all exhibited similar patterns of LOH. Of interest, LOH analysis of 12 distinct microdissected tumors from patient 1542 revealed different patterns to LOH, with 4/12 exhibiting retention of all 16 informative alleles examined (Table 5). Microdissected normal epithelium failed to show evidence of LOH on chromosome 8p, with the exception of specimens derived from patient 1510. All 3 "normal" microdissected foci from patient 1510 exhibited extensive LOH consistent with the pattern of LOH observed in autologous tumor, emphasizing the importance of using PBL as the normal control for this type of study.

-32-

**Table 5** LOH on chromosome 8p in Microdissected Prostate Tissues and Immortalized Cell Lines from Patient 1542

Cell Source	Chromosome 8p Locus			
	D8S133	D8S136	D8S137	D8S131
<u>Microdissected foci</u>				
Normal Epithelium	NL	NL	NL	NL
Tumor				
1	LL	LL	LL	LL
2	nd	nd	NL	NL
3	LL	LL	LL	LL
4	NL	NL	NL	NL
5	LL	LL	NL	NL
6	NL	NL	NL	NL
7	LU	LU	LU	LU
8	NL	NL	NL	NL
9	LU	nd	NL	NL
10	LL	LL	NL	NL
11	LU	LL	NL	NL
12	NL	LL	LL	NL
<u>Cultured Cell Lines</u>				
NPTX (p20) <sup>a</sup>	NL	NL	NL	NL
CP <sub>3</sub> TX (p3,6,13)	NL	NL	NL	NL
CP <sub>3</sub> TX clone 1 <sup>d</sup> (p8)	LL	LL	nd	LL
clone 3 <sup>b</sup> (p8)	nd	NL	nd	NL
clone 4 <sup>c</sup> (p8)	LU	LU	nd	LU
CP <sub>3</sub> TX (p21)	LU	LU	LU	LU
CP <sub>3</sub> TX clone <sup>e</sup> (p23)	LU	LU	LU	LU

No LOH (NL)

Loss of the upper allele (LU)

Loss of the lower allele (LL)

Not determined (nd)

<sup>a</sup>Number of sequential culture passages.

<sup>b</sup>Representative of 7 individual clones.

<sup>c</sup>Representative of 30 individual clones.

<sup>d</sup>Clone 1542-CP<sub>3</sub>TX.8.1

<sup>e</sup>Clone 1542-CP<sub>3</sub>TX.8.4

#### LOH Analysis of Immortalized Cell Lines from Patient 1542.

Loss of heterozygosity in cell cultures generated from patient 1542 was of special interest in light of the diverse patterns of LOH manifested in 12 distinct microdissected tumor foci. This patient was informative at D8S133, D8S136, D8S137, D8S131, D8S339 and ANK. Four of those loci were closely examined for allelic loss in cultures derived from tumor, normal prostate, normal seminal vesicle, and normal fibroblasts (Table 5). Repeated analysis of early passage bulk cultures (passage 3, 6, 13) derived from tumor, designated 1542-CP<sub>3</sub>TX, failed to reveal LOH for any of the four microsatellite markers examined. However, after

-33-

21 serial culture passages (approximately 6 months), 1542-CP,TX exhibited loss of the upper allele at all four loci examined. This pattern of loss was identical to that found in microdissected tumor focus #7. Thirty single cell clones were generated from passage 23 of 1542-CP,TX, and all demonstrated a pattern of LOH identical to that of the uncloned late passage culture and microdissected tumor #7, suggesting the clonal or near clonal composition of the bulk late-passage cell line. These findings also suggested that the failure to detect LOH in early passages of 1542-CP,TX might reflect the presence of multiple tumor clones in the bulk culture having different patterns of LOH, which would preclude the detection of LOH with a PCR-based technique. To investigate this, single cell clones were generated from an early passage (passage 8) of 1542-CP,TX and examined for LOH (Figure 4). Seven of nine clones did not manifest LOH at D8S136 or D8S131, similar to 3/12 microdissected tumors from patient 1542. However, a single clone (clone 4) (1542-CP,TX.8.4) exhibited a pattern of LOH similar to that of microdissected tumor #7, the late passage of 1542-CP,TX and its derivative clones, indicating that the tumor clone(s) that dominated the late passage bulk culture apparently resided in very early culture passages. Of interest, clone 1 (1542-CP,TX.8.1) from the early passage 1542-CP,TX exhibited a different pattern of LOH than that observed for the other 8 early passage clones, with loss of the lower alleles of D8S133, D8S136, and D8S131. This was again consistent with the pattern of LOH detected in two microdissected tumors (#1 and #3). It is important to note that LOH was not detected in repeated experiments with early and late passages of immortalized cultured normal prostatic epithelium, seminal vesicle, or fibroblasts from patient 1542, arguing against the likelihood that the LOH observed in cells derived from tumor was a culture artifact.

**Examination of LOH of Chromosome 8p12-21 in Cell Cultures Derived from the Five Remaining Patients.** In patients 1510 and 1512, LOH was detected at multiple loci in microdissected tumor specimens (Table 4). However, immortalized epithelial cultures generated from corresponding cancer-containing tissue specimens failed to manifest LOH when examined on a bulk level at early or late culture passages. Likewise, clones grown from late culture passages (passage 23 for 1510-CPTX, passage 31 for 1512-CPTX) failed to

-34-

show evidence of LOH. This may reflect the presence of significant amounts of normal prostatic epithelium in the tissue specimens from which these cultures were generated (Table 2), with overgrowth of normal cells *in vitro*. Cloning these cell lines at very early culture passages may yield more rewarding results.

5                   Examination of microdissected tumor foci from patients 1519 (one focus) and 1532 (8 foci) failed to reveal LOH (Table 4). Nevertheless, cultures established from these tumors were assessed for LOH. In the case of patient 1519, examination of the bulk culture 1519-CPTX showed retention of heterozygosity at 6 informative loci which were examined. However, among 11 single cell clones  
10                   derived from culture passage 24 one showed LOH at a single locus, D8S133. In the case of patient 1532, the bulk-cultured line 1532-CP<sub>2</sub>TX, generated from one of two tumor specimens procured (Table 2), showed LOH at D8S133, D8S136 and NEFL but only after prolonged culture (passage 24). All 10 clones generated from the late culture passage also showed the same pattern of loss. However, an  
15                   immortalized culture derived from normal prostate tissue from patient 1532 failed to show evidence of LOH even after 20 culture passages. Likewise, an autologous immortalized fibroblast line retained heterozygosity at the same 3 alleles which were lost in 1532-CP<sub>2</sub>TX. Thus, the LOH observed in a single 1519-CPTX clone and in 1532-CP<sub>2</sub>TX suggests that these findings may reflect LOH existing in an *in situ* tumor focus which was not dissected for analysis.  
20

                  Interesting results were obtained with cultures derived from patient 1535. In this case, extensive LOH was documented in 6 separate microdissected tumor foci, all showing the same pattern of loss (Table 4). Early and late passage cultures generated from prostate cancer, as well as from normal prostate and  
25                   normal seminal vesicle, failed to show LOH. Likewise, 11 tumor clones generated at culture passage 27 failed to show loss. However, cloning of an early passage tumor culture (passage 12) revealed one clone with a pattern of LOH matching the 6 microdissected tumor foci (clone 1535-CP<sub>1</sub>TX.14.3). These results recapitulate those observed with patient 1542 and argue that early cloning of immortalized  
30                   cultures generated from histologically heterogenous prostate cancer specimens may be needed to obtain pure tumor cultures.

-35-

**Expression of MHC Molecules by Immortalized Cell Lines**

**Derived from Prostate Cancer.** Examination of surface MHC expression on immortalized tumor-derived cell lines was of importance in considering the potential usefulness of these lines for immunologic studies. Cultures derived from

5 all 6 patients expressed significant surface levels of MHC class I and the adhesion molecule ICAM-1 as determined by flow cytometry (Table 6).

**Table 6: Cell Surface Expression of MHC and Adhesion Molecules by  
Immortalized Prostate Epithelial Cell Lines**

Patient #	Cell Source	% Positive Cells		
		MHC class I	MHC class II	ICAM-1
1510	F	96	1	57
	CP	90	2	22
1512	NP	100	10	43
	CP	97	6	35
1519	CP	92	3	40
1532	NP	88	1	50
	CP1	89	4	65
	CP2	95	1	74
1535	NP	78	0	44
	SV	96	1	80
	CP1	99	1	60
	CP2	82	1	50
1542	F	87	1	58
	NP	63	2	65
	SV	69	1	87
	CP1	71	1	66
	CP2	72	1	73
	CP3	40	3	64

None of the immortalized lines expressed detectable levels of either MHC class II or the B7 family of co-stimulatory molecules (B7.1, B7.2). However, it was of interest to determine if the expression of MHC molecules could be up-regulated in the presence of IFN- $\gamma$ , as has been reported previously for melanoma cell lines (29). Immortalized tumor derived cell lines 1532-CP,TX, 1535-CP,TX, and 1542-CP,TX were cultured in the presence of 500 U/ml IFN- $\gamma$  for 72 h and then

-37-

assessed for MHC expression. All were induced to express significant amounts of MHC class II molecules. In addition, MHC class I molecule expression was enhanced when compared to untreated controls (Figure 5C vs. 5A). In this light, these immortalized tumor-derived cell lines represent potentially valuable reagents for studying or stimulating CD4<sup>+</sup> and CD8<sup>+</sup> cell-mediated immune responses in patients with primary adenocarcinoma of the prostate.

**HLA Typing of Prostate Epithelial Cell Lines.** HLA typing was conducted for each patient from which prostate epithelial cell lines were derived. A, B and C types were determined by serotyping lymphocytes using methods known in the art. DR and DQ types were determined by genotyping lymphocytes using standard methods. The results of the HLA typing are provided in Table 7.

**TABLE 7**

HLA Types of Prostate Epithelial Cell Lines						
Patient Number	A	B	Cw	DRB1*	DQB1*	DRB
1510	29,31	44,60	3,-	0401,07	0201,0302	4*0101
1512	3,-	7,-	7,-	1501,-	0602,-	5*0101
1519	24,32	14,44	5,8	0701,1301	0201,0603	3*0101, 4*0101
1532	1,-	8,57	6,7	0301,04	0201,0301	3*0101, 4*0101
1535	1,31	7,37	6,7	07,04	0201,0302	4*0101
1542	1,23	50,70	2,-	0301,1101	0201,0301	3*0202

## References

1. Parker, S.L., Tong, T., Bolden, S., and Wingo, P.A. Cancer Statistics, 1996. *CA Cancer J. Clin.*, 65: 5-27, 1996.
- 5 2. Isaacs, J.T., Isaacs, W.B., and Schalken, J. Comparative aspects of multistep prostatic carcinogenesis in humans and rodents. *Prog. Clin. Biol. Res.*, 376: 261-288, 1992.
- 10 3. Webber, M.M., Chaproniere-Rickenberg, D.M., and Donohue, R.E. Isolation and growth of adult human prostatic epithelium in serum-free, defined medium. *In: Methods for serum-free culture of cells of the endocrine system*, pp. 47-61. New York: Alan R. Liss, 1984.
- 15 4. Peehl, D.M. Culture of human prostatic epithelial cells. *In: Culture of epithelial cells*, pp. 159-180. New York: Wiley-Liss, 1992.
- 20 5. Rhim, J.S., Webber, M.M., Bello, D., Lee, M.S., Arnstein, P., Chen, L., and Jay, G. Stepwise immortalization and transformation of adult human prostate epithelial cells by combination of HPV-18 and v-Ki-ras. *Proc. Natl. Acad. Sci. USA*. 91: 11874-11878, 1994.
- 25 6. Bondou, P., Cussenot, O., Soliman, H., Villette, J.M., Teillac, P., LeDuc, A., and Fiet, J. Distinct androgen 5 alpha-reduction pathways in cultured fibroblasts and immortalized epithelial cells from normal human adult prostate. *J. Urol.*, 152: 226-231, 1994.
- 30 7. Lee, M., Garkovenko, E., Yun, J.S., Weijerman, P.C., Peehl, D.M., Chen, L., and Rhim, J.S. Characterization of adult human prostatic epithelial cells immortalized by polybrene-induced DNA transfection with a plasmid containing an origin-defective SV40 genome. *Int. J. Oncol.*, 4: 821-830, 1994.



-39-

8. Weijerman, P.C., König J.J., Wong, S.T., Niesters, G.M., and Peehl, D.M. Lipofection-mediated immortalization of human prostatic epithelial cells of normal and malignant origin using human papillomavirus type 18 DNA. *Cancer Res.*, 54: 5579-5583, 1994.
- 5
9. Brothman, A.R., Peehl, D.M., Patel, A.M., and McNeal, J.E. Frequency and pattern of karyotypic abnormalities in human prostate cancer. *Cancer Res.*, 50: 3795-3803, 1990.
- 10
10. Brothman, A.R., Peehl, D.M., Patel, A.M., MacDonald, G.R., McNeal, J.E., Ladaga, L.E., and Schellhammer, P.F. Cytogenetic evaluation of 20 cultured primary prostatic tumors. *Cancer Genet. Cytogenet.*, 55: 79-84, 1991.
- 15
11. Brothman, A.R., Patel, A.M., Peehl, D.M., and Schellhammer, P.F. Analysis of prostatic tumor cultures using fluorescence in-situ hybridization (FISH). *Cancer Genet. Cytogenet.*, 62: 180-185, 1992.
- 20
12. Isaacs, W.B., Bova, G.S., Morton, R.A., Bussemakers, J.D., and Ewing, C.M. Molecular biology of prostate cancer. *Seminars in Oncology*, 21: 514-521, 1994.
- 25
13. Carter, B.S., Ewing, C.M., Ward, W.S., Treiger, B.F., Aalders, T.W., Schalken, J.A., Epstein, J.I., and Isaacs, W.B. Allelic loss of chromosomes 16q and 10q in human prostate cancer. *Proc. Natl. Acad. Sci. USA.* 87: 8751-8755, 1990.
- 30
14. Bergenheim, U.S.R., Kunimi, K., Collins, V.P., and Ekman, P. Deletion mapping of chromosomes 8, 10, and 16 in human prostatic carcinoma. *Genes, Chromosomes and Cancer*, 3: 215-220, 1991.

-40-

15. Sakar, W.A., Macoska, J.A., Benson, P., Grignon, D.J., Wolman, S.R., Pontes, J.E., and Crissman, J.D. Allelic loss in locally metastatic, multisampled prostate cancer. *Cancer Res.*, 54: 3273-3277, 1994
- 5 16. Bova, G.S., Carter, B.S., Bussemakers, M.J.G., Emi, M., Fujiwara, Y., Kyprianou, N., Jacobs, S.C., Robinson, J.C., Epstein, J.I., Walsh, P.C., and Isaacs, W.B. Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. *Cancer Res.*, 53: 3869-3873, 1993.
- 10 17. Trapman, J., Sleddens, H.F.B.M., van der Weiden, M.M., Dinjens, W.N.M., Konig, J.J., Schroder, F.H., Faber, P.W., and Bosman, F.T. Loss of heterozygosity of chromosome 8 microsatellite loci implicates a candidate tumor suppressor gene between the loci D8S87 and D8S133 in human prostate cancer. *Cancer Res.*, 54: 6061-6064, 1994.
- 15 18. Macoska, J.A., Trybus, T.M., Benson, P.D., Sakr, W.A., Grignon, D.J., Wojno, K.D., Pietruk, T., and Powell, I.J. Evidence for three tumor suppressor gene loci on chromosome 8p in human prostate cancer. *Cancer Res.*, 55: 5390-5395, 1995.
- 20 19. Vocke, C.D., Pozzatti, R.O., Bostwick, D.G., Florence, C.D., Jennings, S.B., Strup, S.E., Duray, P.H., Liotta, L.A., Emmert-Buck, M.R., and Linehan, W.M. Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p12-21. *Cancer Res.*, 56: 2411-2416, 1996.
- 25 20. Emmert-Buck, M.R., Vocke, C.D., Pozzatti, R.O., Duray, P.H., Jennings, S.B., Florence, C.D., Zhuang, Z., Bostwick, D.G., Liotta, L.A., and Linehan, W.M. Allelic loss on chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia. *Cancer Res.*, 55: 2959-2962, 1995.
- 30

-41-

21. Topalian, S.L., Muul, L.M., Solomon, D., and Rosenberg, S.A. Expansion of human infiltrating lymphocytes for use in immunotherapy trials. *J. Immunol. Meth.*, 102: 127-141, 1987.
- 5 22. Halbert, C.L., Demers, G.W., and Galloway, D.A. The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells. *J. Virol.*, 65: 473-478. 1991.
- 10 23. Topalian, S.L., Solomon, D., Avis, F.P., Chang, A.E., Freerksen, D.L., Linehan, W.M., Lotze, M.T., Robertson, C.N., Seipp, C.A., Simon, P., Simpson, C.G., and Rosenberg, S.A. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: A pilot study. *J. Clin. Oncol.*, 6: 839-853, 1988.
- 15 24. Emmert-Buck, M.R., Roth, M.J., Zhuang, Z., Campo, E., Rozhin, J., Sloane, B.F., Liotta, L.A., Stetler-Stevenson, W.G. Increased gelatinase A and cathepsin B activity in invasive tumor regions of human colon cancer samples. *Am. J. Pathol.*, 154: 1285-1290, 1994.
- 20 25. Zhuang, Z., Berttheau, P., Emmert-Buck, M.R., Liotta, L.A., Gnarr, J., Linehan, W.M., Lubensky, I.A. A new microdissection technique for archival DNA analysis of specific cell populations in lesions less than one millimeter. *Am. J. Pathol.*, 146: 620-625, 1995.
- 25 26. Zhuang, Z., Merino, M.J., Chuaqui, R., Liotta, L.A., and Emmert-Buck, M.R. Identical allelic loss on chromosome 11q13 in microdissected in situ and invasive human breast cancer. *Cancer Res.*, 55: 467-471, 1995.
- 30 27. Hung, T., Mak, K., and F ng, K.A. A specificity enhancer for polymerase chain reaction. *Nucleic Acid Res.*, 18: 4953, 1990.

-42-

28. Litt, M., Hauge, X., and Sharma, V. Shadow bands seen when typing polymorphic dinucleotide repeats: some causes and cures. *Biotechniques*, 15: 280-284, 1993.
- 5 29. Markus, N.R., Rosenberg, S.A., and Topalian, S.L. Analysis of cytokine secretion by melanoma-specific CD4+ T lymphocytes. *J. Interferon Cytokine Res.*, 15: 739-746, 1995.
- 10 30. Burrows, M.T., Burns, J.E., and Suzuki, Y. Studies on the growth of cells. The cultivation of bladder and prostatic tumors outside the body. *J. Urol.* 1: 3, 1917.
- 15 31. Horoszewicz, J.S., Leong, S.S., Kawinski, E., Karr, J.P., Rosenthal, H., Chu, T.M., Mirand, E.A., and Murphy, G.P. LNCaP model of prostatic carcinoma. *Cancer Res.*, 43: 1809-1818, 1983.
- 20 32. Henttu, P., Liao, S., and Vihko, P. Androgens up-regulate the human prostate specific antigen messenger ribonucleic acid (mRNA), but down-regulate the prostatic acid phosphatase mRNA in the LNCaP cell line. *Endocrinology*, 130: 766-772, 1992.
33. Cooney, E.L. et al 1991 Lancet Vol. 337:567.
- 25 34. Wolff, J.A. et al 1990 Science Vol. 247:1465.
35. Davis, H.L. et al 1993 Hum. Gene Ther. Vol. 4:151.
36. Yang, N.S. et al 1990 Proc. Natl. Acad. Sci USA Vol. 87:9568.
- 30 37. Williams, R.S. et al 1991 Proc. Nat'l Acad. Sci USA Vol. 88:2726.

-43-

38. Fynan, E.R. et al 1995 Proc. Natl. Acad. Sci USA Vol. 90:11478.
39. Eisenbraun, M.D. et al 1993 DNA and Cell Biol. Vol 12:791.
40. Fuller, D.H. et al 1994 AIDS Res. Hum. Retrovir. Vol 10(11):1433.
41. Acsadi, G. et al 1991 Nature Vol. 352:815.
42. Matteucci, M.D. et al 1996, Nature vol. 384:20-22.
43. Perkus et al Science 1985 Vol. 229:981-984.
44. Kaufman et al Int. J. Cancer 1991, Vol. 48:900-907.
45. Moss Science 1991 Vol. 252:1662.
46. Smith and Moss BioTechniques Nov/Dec 1984, p. 306-312.
47. U.S. Patent No. 4,738,846.
48. Sutter and Moss Proc. Nat'l Acad. Sci USA 1992 Vol. 89:10847-10851.
49. Baxby and Paoletti Vaccine 1992 Vol. 10:8-9.
50. PCT International Publication No. WO94/16716 published August 4, 1994.

51. Short Protocols in Molecular Biology, 3rd ed. F. Ausubel et al, eds. John Wiley & Son, Inc., 1995.

52. Basic Methods in Molecular Biology, 2nd ed. L. Davis et al,  
5 eds. Appleton & Lange, 1994.

- 45 -

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

- (i) APPLICANTS: THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, HEALTH AND HUMAN SERVICES, ET AL
- (ii) TITLE OF INVENTION: IMMORTAL HUMAN PROSTATE EPITHELIAL CELL CULTURES AND CLONES AND THEIR APPLICATIONS IN THE RESEARCH AND THERAPY OF PROSTATE CANCER
- (iii) NUMBER OF SEQUENCES: 16
- (iv) CORRESPONDENCE ADDRESS:
  - (A) ADDRESSEE: MORGAN & FINNEGAN
  - (B) STREET: 345 PARK AVENUE
  - (C) CITY: NEW YORK
  - (D) STATE: NEW YORK
  - (E) COUNTRY: USA
  - (F) ZIP: 10154
- (v) COMPUTER READABLE FORM:
  - (A) MEDIUM TYPE: DISKETTE - 3.5 INCH, 1.44 MB STORAGE
  - (B) COMPUTER: IBM PC COMPATIBLE
  - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
  - (D) SOFTWARE: WORDPERFECT 5.1
- (vi) CURRENT APPLICATION DATA:
  - (B) FILING DATE: 30-JAN-1997
- (vii) PRIOR APPLICATION DATA:
  - (A) APPLICATION NUMBER: 60/011042
  - (B) FILING DATE: 02-FEB-1996
- (viii) ATTORNEY/AGENT INFORMATION:
  - (A) NAME: KATHRYN M. BROWN
  - (B) REGISTRATION NUMBER: 34,556
  - (C) REFERENCE/DOCKET NUMBER: 2026-4217PC
- (ix) TELECOMMUNICATION INFORMATION:
  - (A) TELEPHONE: (212) 758-4800
  - (B) TELEFAX: (212) 751-6849
  - (C) TELEX: 421792

## (2) INFORMATION FOR SEQ ID NO:1:

- 46 -

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 19 BASE PAIRS  
(B) TYPE: NUCLEIC ACID  
(C) STRANDEDNESS: SINGLE  
(D) TOPOLOGY: LINEAR

- (ii) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GAGCCCAGAC AGGCTGGAA

19

- (3) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 21 BASE PAIRS  
(B) TYPE: NUCLEIC ACID  
(C) STRANDEDNESS: SINGLE  
(D) TOPOLOGY: LINEAR

- (ii) SEQUENCE DESCRIPTION: SEQ ID NO:2:

ACTTTTCTGG CCAAACCTCCT G

21

- (4) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 20 BASE PAIRS  
(B) TYPE: NUCLEIC ACID  
(C) STRANDEDNESS: SINGLE  
(D) TOPOLOGY: LINEAR

- (ii) SEQUENCE DESCRIPTION: SEQ ID NO:3:

CAGGTGGGAA AACTGAGGGA

20

- (5) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 22 BASE PAIRS  
(B) TYPE: NUCLEIC ACID  
(C) STRANDEDNESS: SINGLE  
(D) TOPOLOGY: LINEAR

- (ii) SEQUENCE DESCRIPTION: SEQ ID NO:4:

AGCAACTGTC AACATATTGC TC

22

- (6) INFORMATION FOR SEQ ID NO:5:



- 47 -

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 19 BASE PAIRS  
(B) TYPE: NUCLEIC ACID  
(C) STRANDEDNESS: SINGLE  
(D) TOPOLOGY: LINEAR

- (ii) SEQUENCE DESCRIPTION: SEQ ID NO:5:

GCCCAAAGAG GAGAATAAA

19

- (7) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 18 BASE PAIRS  
(B) TYPE: NUCLEIC ACID  
(C) STRANDEDNESS: SINGLE  
(D) TOPOLOGY: LINEAR

- (ii) SEQUENCE DESCRIPTION: SEQ ID NO:6:

CTGTTTCCAC ACCGAAGC

18

- (8) INFORMATION FOR SEQ ID NO:7:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 20 BASE PAIRS  
(B) TYPE: NUCLEIC ACID  
(C) STRANDEDNESS: SINGLE  
(D) TOPOLOGY: LINEAR

- (ii) SEQUENCE DESCRIPTION: SEQ ID NO:7:

GCAGTAGTGC CGCAGTTTCA

20

- (9) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 20 BASE PAIRS  
(B) TYPE: NUCLEIC ACID  
(C) STRANDEDNESS: SINGLE  
(D) TOPOLOGY: LINEAR

- (ii) SEQUENCE DESCRIPTION: SEQ ID NO:8:

TGCAATTCAT CTCCTTTCT

20

- (10) INFORMATION FOR SEQ ID NO:9:

- 48 -

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 22 BASE PAIRS  
(B) TYPE: NUCLEIC ACID  
(C) STRANDEDNESS: SINGLE  
(D) TOPOLOGY: LINEAR
- (ii) SEQUENCE DESCRIPTION: SEQ ID NO:9:  
AAATACCGAG ACTCACACTA TA 22
- (11) INFORMATION FOR SEQ ID NO:10:
- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 21 BASE PAIRS  
(B) TYPE: NUCLEIC ACID  
(C) STRANDEDNESS: SINGLE  
(D) TOPOLOGY: LINEAR
- (ii) SEQUENCE DESCRIPTION: SEQ ID NO:10:  
GCTAATCAGG GAATCACCCA A 21
- (12) INFORMATION FOR SEQ ID NO:11:
- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 22 BASE PAIRS  
(B) TYPE: NUCLEIC ACID  
(C) STRANDEDNESS: SINGLE  
(D) TOPOLOGY: LINEAR
- (ii) SEQUENCE DESCRIPTION: SEQ ID NO:11:  
ACATAGGCTG GAGAGTCACA GG 22
- (13) INFORMATION FOR SEQ ID NO:12:
- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 22 BASE PAIRS  
(B) TYPE: NUCLEIC ACID  
(C) STRANDEDNESS: SINGLE  
(D) TOPOLOGY: LINEAR
- (ii) SEQUENCE DESCRIPTION: SEQ ID NO:12:  
GGATGAGGCT CAGCACACAA GC 22
- (14) INFORMATION FOR SEQ ID NO:13:

- 49 -

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 18 BASE PAIRS  
(B) TYPE: NUCLEIC ACID  
(C) STRANDEDNESS: SINGLE  
(D) TOPOLOGY: LINEAR

- (ii) SEQUENCE DESCRIPTION: SEQ ID NO:13:

TAGATGTTAC CATTTCAC

18

- (15) INFORMATION FOR SEQ ID NO:14:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 18 BASE PAIRS  
(B) TYPE: NUCLEIC ACID  
(C) STRANDEDNESS: SINGLE  
(D) TOPOLOGY: LINEAR

- (ii) SEQUENCE DESCRIPTION: SEQ ID NO:14:

GATTAGATCT TGGATCAG

18

- (16) INFORMATION FOR SEQ ID NO:15:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 20 BASE PAIRS  
(B) TYPE: NUCLEIC ACID  
(C) STRANDEDNESS: SINGLE  
(D) TOPOLOGY: LINEAR

- (ii) SEQUENCE DESCRIPTION: SEQ ID NO:15:

TCCCAGATCG CTCTACATGA

20

- (17) INFORMATION FOR SEQ ID NO:16:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 20 BASE PAIRS  
(B) TYPE: NUCLEIC ACID  
(C) STRANDEDNESS: SINGLE  
(D) TOPOLOGY: LINEAR

- (ii) SEQUENCE DESCRIPTION: SEQ ID NO:16:

CACAGCTTCA GAAGTCACAG

20

-50-

## WE CLAIM:

1. An isolated, immortalized, malignant, human, adult prostate epithelial cell line.
2. An immortalized, malignant, human, adult prostate epithelial cell line according to claim 1 characterized as having at least one allelic loss of heterozygosity.
3. The immortalized, malignant, human, adult prostate epithelial cell line according to claim 2, wherein the allelic loss is at one or more chromosomes.
4. The immortalized, malignant, human, adult prostate epithelial cell line according to claim 3, wherein the chromosomes are selected from the group consisting of: chromosome 1, chromosome 8, chromosome 10, chromosome 16, and combinations thereof.
5. The immortalized, malignant, human prostate epithelial cell line according to claim 2, wherein the allelic loss is on chromosome 8p.
6. The immortalized, malignant, human prostate epithelial cell line according to claim 2, wherein the allelic loss is on chromosome 8p11-21.
7. The immortalized, malignant, human prostate epithelial cell line according to claim 2, wherein the allelic loss is at more than one locus.
8. The immortalized, malignant cell line according to claim 6, wherein the loss occurs at a locus selected from the group consisting of SFTP-2, D8S133, D8S136, D8S131, NEFL, D8S137, D8S339, ANK and combinations thereof.
9. A cloned, immortalized malignant prostate epithelial cell line having the identifying characteristics of a cloned, immortalized, malignant prostate epithelial cell line 1535-CP, TX.14.3 deposited as ATCC CRL-12263 with the ATCC.
10. A cloned, immortalized, malignant prostate epithelial cell line having the identifying characteristics of a cloned, immortalized, malignant prostate epithelial cell line 1542-CP, TX.8.4 deposited as ATCC CRL-12264 with the ATCC.

-51-

11. A cloned, immortalized, malignant prostate epithelial cell line having the identifying characteristic of a cloned, immortalized, malignant prostate epithelial cell line 1542-CP,TX.8.1 deposited as ATCC CRL-12265 with the ATCC.

5 12. A cloned, immortalized, malignant prostate epithelial cell line 1535-CP,TX.14.3 deposited as ATCC CRL-12263 with the ATCC.

13. A cloned, immortalized, malignant prostate epithelial cell line 1542-CP,TX.8.4 deposited as ATCC CRL-12264 with the ATCC.

10 14. A cloned, immortalized, malignant prostate epithelial cell line 1542-CP,TX.8.1 deposited as ATCC CRL-12265 with the ATCC.

15. An immortalized, malignant, human, adult prostate epithelial cell line 1532-CP2TX deposited as CRL-12038 with the ATCC.

16. An immortalized, malignant, human, adult prostate epithelial cell line 1535-CP,TX deposited as CRL-12041 with the ATCC.

15 17. An immortalized, malignant, human, adult prostate epithelial cell line 1542-CP3TX deposited as CRL 12037 with the ATCC.

18. A cloned, immortalized, malignant, human, adult prostate epithelial cell line produced by a method comprising:

- 20 A. isolation and initiation of cell culture of epithelial cells from a primary prostatic tumor,  
B. immortalization of the prostate epithelial cells,  
C. single cell cloning of the immortalized, malignant, adult prostate epithelial cell line, and,  
D. analysis of malignant prostate epithelial cells or clones for at  
25 least one allelic loss of heterozygosity.

19. The cloned immortalized human malignant prostate epithelial cell line according to claim 18, wherein allelic loss occurs on chromosome 1, 8, 10, 16 or combination thereof.

30 20. An immortalized, normal human adult prostate epithelial cell line 1532-NPTX deposited as CRL-12036 with the ATCC.

21. An immortalized, normal human adult prostate epithelial cell line 1535-NPTX deposited as CRL-12039 with the ATCC.

-52-

22. An immortalized, normal human adult prostate epithelial cell line 1542-NPTX deposited as CRL-12040 with the ATCC.

23. A composition comprising:

A) an immortalized malignant human adult prostate epithelial cell, and

B) an autologous immortalized, normal human adult prostate epithelial cell.

24. The composition according to claim 23 wherein the immortalized malignant human adult prostate epithelial cell line is 1532-CP2TX deposited as CRL-12038 with the ATCC and the autologous immortalized, normal human adult prostate epithelial cell line is 1532-NPTX deposited as CRL-12036 with the ATCC.

25. The composition according to claim 23 wherein the immortalized malignant human adult prostate epithelial cell line is 1535-CP1TX deposited as CRL-12041 with the ATCC and the autologous immortalized, normal human adult prostate epithelial cell line is 1535-NPTX deposited as CRL-12039 with the ATCC.

26. The composition according to claim 23 wherein the immortalized, malignant human adult prostate epithelial cell line is 1542-CP3TX deposited as CRL12037 with the ATCC and the autologous immortalized, normal human adult prostate epithelial cell line is 1542-NPTX deposited as CRL-12040 with the ATCC.

27. A pharmaceutical composition comprising an immortalized, human, adult, prostate epithelial cell line, clone, or portion thereof according to claims 1-22 and a pharmaceutically acceptable carrier.

28. The pharmaceutical composition according to claim 27 further comprising an adjuvant, costimulatory molecule, cytokine, chemokine, adhesion molecule, an MHC molecule or combination thereof.

29. An immunogen for eliciting an immune response specific for a prostate cancer protein or portion thereof comprising an immortalized, human, adult, prostate epithelial cell line, clone or immunogenic portion thereof, according to claims 1-20.

-53-

30. The immunogen according to claim 29 further comprising an adjuvant, cytokine, costimulatory molecule, chemokine, adhesion molecule, an MHC molecule or combination thereof.

5 31. The immunogen according to claim 29, wherein the immune response is a cell mediated response.

32. The immunogen according to claim 29, wherein the immune response is humoral response.

33. An antibody immunoreactive with the immunogen according to claim 29.

10 34. A prostate cancer vaccine comprising an immortalized, malignant, human, adult, prostate epithelial cell line or clone according to claims 1-22 or portion thereof.

15 35. The prostate cancer vaccine according to claim 34, further comprising one or more genes encoding cytokines, chemokines, costimulatory molecules, adhesion molecules, or MHC molecules incorporated into said cell.

36. A method of screening for a potential therapeutic agent comprising exposing an immortalized, adult, prostate epithelial cell according to claims 1-22 to the agent to be tested and assessing the effect of the agent on the cell.

20 37. The method according to claim 36, wherein the effect is cytotoxicity.

38. The method according to claim 36, wherein the effect is inhibition of cell growth.

25 39. A kit comprising at least one immortalized, adult, prostate epithelial cell line according to claims 1-22.

40. The kit according to claim 39 wherein the kit comprises:

A) an immortalized normal cell line and,

B) an immortalized malignant cell line, wherein the normal and malignant cell lines are derived from the same individual.


30 41. Method of selecting an immortalized malignant, human, adult prostate epithelial cell line from a source comprising:

-54-

- 5
- A. single cell cloning of an immortalized, human, adult prostate epithelial cell line, and
  - B. selecting cells which have at least one allelic loss of heterozygosity on at least one chromosome, said loss is indicative of the immortalized malignant, human, adult prostate epithelial cell.
42. The method of claim 41, wherein the source is a cell culture of prostate cells.
43. The method of claim 41, wherein the chromosome is selected from the group consisting of 1, 8, 10, 16 and combinations thereof.
44. The method of claim 43, wherein the chromosome is 8p.
45. The method of claim 44, wherein the loss is on at least one allele selected from the region 8p11-21.



FIGURE 1A




**FIG. 1B**



FIG. 2



FIGURE 3





# FIG. 4

D8S136

---

1 2 3 4 5 6





# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 97/01430

**A. CLASSIFICATION OF SUBJECT MATTER**  
 IPC 6 C12N5/10 A61K35/48 C07K16/18 G01N33/50

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
 IPC 6 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CANCER RESEARCH, vol. 54, 1 November 1994, pages 5579-5583, XP002030997 WEIJERMAN ET AL: "LIPOFECTION-MEDIATED IMMORTALIZATION OF HUMAN PROSTATIC EPITHELIAL CELLS OF NORMAL AND MALIGNANT ORIGIN USING HUMAN PAPILLOMAVIRUS TYPE 18 DNA" cited in the application see the whole document ---	1,23, 27-40
A	CANCER RESEARCH, vol. 55, 15 July 1995, pages 2959-2962, XP002030998 EMMERT-BUCK ET AL: "ALLELIC LOSS ON CHROMOSOME 8P12-21 IN MICRODISSECTED PROSTATIC INTRAEPITHELIAL NEOPLASIA" cited in the application ---	

-/--

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

15 May 1997

Date of mailing of the international search report

27.05.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax (+ 31-70) 340-3016

Authorized officer

Sitch, W

# INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 97/01430

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 95 29994 A (UNIV MICHIGAN ;US HEALTH (US)) 9 November 1995 see page 5, line 12 - line 27 ---	
A	WO 95 29990 A (UNIV MICHIGAN ;US HEALTH (US)) 9 November 1995 see page 3, line 30 - page 4, line 12 -----	



**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No

PCT/US 97/01430

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9529994 A	09-11-95	US 5610043 A	11-03-97
		CA 2187099 A	09-11-95
-----			
WO 9529990 A	09-11-95	CA 2187088 A	09-11-95
-----			

